secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2023-12-20T23:59:59+00:00
Accession:  0000950170-23-071896
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atara closes expanded tab-cel partnership with Pierre Fabre; receives ~$27M upfront, up to $640M total
--------------------------------------------------------------------------------

- Pierre Fabre gets development, manufacturing, commercialization rights for tab-cel in US and all remaining markets.
- Atara receives ~$27M cash upfront and initial inventory purchase; potential milestones up to $640M total.
- Potential $100M in regulatory milestones through BLA approval; significant double-digit tiered royalties on net sales.
- Pierre Fabre to reimburse global development costs through BLA transfer; manufacturing transition planned at BLA transfer.
- Atara plans to submit tab-cel BLA for PTLD to FDA in Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000095017023071896/0000950170-23-071896-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000095017023071896/atra-20231220.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-071896

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer